A Unified OS for Drug Development: Our Investment in Cheiron

Getting a new drug approved is brutal by design. Ten years, billions of dollars, and a 90% failure rate — that's the baseline. A lot of that grind isn't scientific difficulty so much as organizational chaos: clinical, regulatory, manufacturing, and commercial teams all generate mountains of knowledge that never talk to each other. Scientists end up playing detective, chasing down context buried in someone else's spreadsheet instead of actually making decisions. Cheiron, a Stanford-founded startup, just raised an $8 million seed round led by Menlo Ventures to fix exactly that.

The backers list reads like a biotech all-star roster. Moderna co-founder Robert Langer, former Pfizer chief medical officer Freda Lewis-Hall, Chai Discovery's Josh Meier, ex-Starbucks CEO Laxman Narasimhan, and former Apple AI chief John Giannandrea are all in. That's not a coincidence — Cheiron's pitch is essentially building a queryable brain for an entire drug program, something called the Lifesciences Knowledge Graph, which pulls together biomedical, clinical, regulatory, patent, and commercial data and maps it onto a specific company's pipeline.

The idea is that every drug program rests on one core claim — this molecule treats this disease safely and effectively — and that claim has to survive scrutiny from regulators, competitors, and internal safety reviews for years on end. Right now, that argument lives in fragments: hundreds of documents, dozens of people, no single source of truth. Cheiron's platform lets teams ask direct questions — does the safety story still hold up against new data, does the trial design survive the latest FDA precedent — and get answers traceable back to their source, not just AI-generated guesswork.

What's notable here isn't the vision so much as the traction behind it. In under six months, Cheiron says it's already reached over 20% of Korea's biopharma workforce and signed seven of the country's top ten pharma companies as customers. That's a fast, concentrated adoption curve for enterprise software in a notoriously slow-moving industry, and it's now leading Cheiron into pilots with major global pharma players as it pushes into the U.S.

Founders Minseok Bae, Jason Park, and Harshit Gupta met at Stanford, and Menlo's framing leans hard on their customer obsession rather than just their technical chops in competitive programming, biology, and physics. For Menlo, Cheiron slots into a growing thesis bet on AI-and-biology startups, joining Chai Discovery, Phylo, and Aurora Therapeutics in the firm's portfolio — a signal that VCs increasingly see pharma's data mess, not molecule discovery itself, as the next big AI opportunity.